Voice your opinion on congressional bill HR2087-116 and let lawmakers know your stance with UnPac!

Main Subject: Health

Drug Price Transparency Act

This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

HR19-116, HR2113-116, HR2296-116, S2051-116, S3129-116, HR1570-116,

House committee actions Actions

Committee
May. 21 2019	Subcommittee Hearings Held.
Apr. 05 2019	Referred to the Subcommittee on Health.
Apr. 04 2019	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral

Apr. 04
2019

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Library of Congress Actions

IntroReferral
Apr. 04 2019	Introduced in House Introduced in House

House bill HR2087-116

Drug Price Transparency Act

Promote the cause!

Or use this QR code